Bausch Health Cos Inc. (NYSE:BHC) Given Consensus Rating of “Hold” by Analysts

Shares of Bausch Health Cos Inc. (NYSE:BHC) have been given an average recommendation of “Hold” by the six analysts that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation. The average 12 month price target among brokers that have covered the stock in the last year is $8.50.

BHC has been the topic of a number of analyst reports. Truist Financial lifted their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a report on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of Bausch Health Cos in a report on Monday, December 29th. Barclays assumed coverage on shares of Bausch Health Cos in a research note on Monday, December 8th. They issued an “equal weight” rating and a $8.00 price objective for the company. Raymond James Financial raised shares of Bausch Health Cos to a “hold” rating in a research report on Monday, December 15th. Finally, Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st.

Hedge Funds Weigh In On Bausch Health Cos

A number of hedge funds and other institutional investors have recently made changes to their positions in BHC. Northwestern Mutual Wealth Management Co. increased its holdings in Bausch Health Cos by 6,661.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after buying an additional 5,329 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Bausch Health Cos by 65.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after acquiring an additional 3,106 shares during the period. Alpha Wealth Funds LLC bought a new position in shares of Bausch Health Cos during the 2nd quarter valued at approximately $65,000. Stratos Wealth Advisors LLC purchased a new stake in shares of Bausch Health Cos during the 2nd quarter worth approximately $67,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Bausch Health Cos in the 1st quarter worth approximately $68,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Cos Stock Down 4.6%

BHC stock opened at $7.42 on Friday. The firm has a market capitalization of $2.75 billion, a PE ratio of 7.64 and a beta of 0.37. The company has a quick ratio of 0.97, a current ratio of 1.30 and a debt-to-equity ratio of 57.48. Bausch Health Cos has a twelve month low of $4.25 and a twelve month high of $8.69. The stock’s 50 day moving average is $6.84 and its 200-day moving average is $6.75.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.